Stem definition | Drug id | CAS RN |
---|---|---|
antibacterials, nalidixic acid derivatives | 1875 | 389-08-2 |
Dose | Unit | Route |
---|---|---|
4 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.43 mg/mL | Bocci G, Oprea TI, Benet LZ |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 287.20 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 96 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
March 6, 1964 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Idiopathic intracranial hypertension | 25.79 | 23.51 | 3 | 3 | 2928 | 63486088 |
None
None
None
Source | Code | Description |
---|---|---|
ATC | J01MB02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Other quinolones |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D059005 | Topoisomerase II Inhibitors |
MeSH PA | D059003 | Topoisomerase Inhibitors |
CHEBI has role | CHEBI:33281 | antibiotics |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:59517 | DNA synthesis inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Bacterial urinary infection | indication | 312124009 | |
Disorder of the central nervous system | contraindication | 23853001 | DOID:331 |
Tendinitis | contraindication | 34840004 | DOID:971 |
Acute nephropathy | contraindication | 58574008 | |
Anemia due to enzyme deficiency | contraindication | 111577008 | |
Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
Seizure disorder | contraindication | 128613002 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Peripheral nerve disease | contraindication | 302226006 | |
Pseudomembranous enterocolitis | contraindication | 397683000 | |
Traumatic rupture of tendon | contraindication | 415749005 | |
Porphyria | contraindication | 418470004 | |
Severe Cerebral Arteriosclerosis | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.27 | acidic |
pKa2 | 0.86 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 2B | GPCR | IC50 | 5.10 | WOMBAT-PK | |||||
Pyruvate kinase PKM | Enzyme | IC50 | 4.28 | CHEMBL | |||||
DNA gyrase | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
ID | Source |
---|---|
4018247 | VUID |
N0000146578 | NUI |
D00183 | KEGG_DRUG |
4018247 | VANDF |
C0027353 | UMLSCUI |
CHEBI:100147 | CHEBI |
NIX | PDB_CHEM_ID |
CHEMBL5 | ChEMBL_ID |
DB00779 | DRUGBANK_ID |
D009268 | MESH_DESCRIPTOR_UI |
4421 | PUBCHEM_CID |
12773 | IUPHAR_LIGAND_ID |
1450 | INN_ID |
3B91HWA56M | UNII |
618425 | RXNORM |
2063 | MMSL |
5148 | MMSL |
d00157 | MMSL |
002860 | NDDF |
387261006 | SNOMEDCT_US |
47602007 | SNOMEDCT_US |
None